Overview
flowchart TD
PSP["PSP"] -->|"associated with"| Alzheimer["Alzheimer"]
PSP["PSP"] -->|"associated with"| Als["Als"]
PSP["PSP"] -->|"associated with"| Alzheimer_s_disease["Alzheimer's disease"]
PSP["PSP"] -->|"expressed in"| neurons["neurons"]
PSP["PSP"] -->|"downregulates"| SV2A["SV2A"]
PSP["PSP"] -->|"targets"| tauopathy["tauopathy"]
PSP["PSP"] -->|"participates in"| unfolded_protein_response["unfolded protein response"]
PSP["PSP"] -->|"regulates"| STX6["STX6"]
PSP["PSP"] -->|"associated with"| frontotemporal_dementia["frontotemporal dementia"]
PSP["PSP"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
PSP["PSP"] -->|"associated with"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"regulates"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"associated with"| tauopathy["tauopathy"]
PSP["PSP"] -->|"biomarker for"| Ms["Ms"]
style PSP fill:#4fc3f7,stroke:#333,color:#000
Lithium carbonate has been investigated as a potential disease-modifying treatment for Progressive Supranuclear Palsy (PSP) based on its neuroprotective properties. Lithium inhibits glycogen synthase kinase-3 beta (GSK-3beta), a key kinase involved in tau phosphorylation. Despite strong preclinical rationale, clinical trials in PSP have shown limited efficacy.[@clinicaltrialsgov][@hampel]
Trial Details
...Overview
Mermaid diagram (expand to render)
Lithium carbonate has been investigated as a potential disease-modifying treatment for Progressive Supranuclear Palsy (PSP) based on its neuroprotective properties. Lithium inhibits glycogen synthase kinase-3 beta (GSK-3beta), a key kinase involved in tau phosphorylation. Despite strong preclinical rationale, clinical trials in PSP have shown limited efficacy.[@clinicaltrialsgov][@hampel]
Trial Details
| Parameter | Details |
|-----------|---------|
| Drug Name | Lithium Carbonate |
| Mechanism | GSK-3β inhibitor |
| Phase | Phase 2 |
| Status | Completed |
| Key Trial | NCT00703677 |
Mechanism of Action
Lithium exerts several neuroprotective effects relevant to PSP:
GSK-3β inhibition - Lithium directly inhibits GSK-3β, reducing tau phosphorylation at multiple sites
Neurotrophic effects - Promotes brain-derived neurotrophic factor (BDNF) signaling
Anti-apoptotic effects - Inhibits pro-apoptotic pathways
Anti-inflammatory effects - Modulates microglial activationRationale for PSP
The rationale for lithium in PSP is strong:
- GSK-3β hyperactivity - Post-mortem studies show increased GSK-3β activity in PSP brains
- Tau hyperphosphorylation - GSK-3β is a major tau kinase contributing to NFT formation
- Preclinical evidence - Lithium reduces tau pathology in animal models
- Clinical safety - Lithium has a well-established safety profile in humans
Clinical Trial Results
NCT00703677: Randomized Controlled Trial (2007-2009)
The primary clinical trial (NCT00703677) was a Phase 2 randomized, double-blind, placebo-controlled trial conducted at multiple centers to evaluate lithium carbonate in patients with PSP[@hampel][@toulouse2009].
Trial Design:
- 12-week treatment period with 4-week washout
- Lithium titrated to target serum levels of 0.8-1.2 mEq/L
- Primary endpoint: Change in PSP Rating Scale (PSPRS)
- Secondary endpoints: CSF biomarkers, MRI measures
Key Findings:| Outcome | Result |
|---------|--------|
| Primary (PSPRS change) | No significant difference vs placebo |
| Tau biomarkers | No significant reduction in CSF tau |
| Tolerability | Acceptable safety profile |
| Discontinuation | 20% (due to side effects or disease progression) |
Published Results (Hampel et al., 2009):
- Sample size: 42 patients with probable PSP
- Primary outcome: No statistically significant difference in PSPRS change between lithium and placebo groups
- Tau biomarkers: Lithium treatment did not significantly reduce CSF tau levels compared to baseline or placebo
- Safety: Adverse events were mild to moderate; most common were tremor, fatigue, and GI symptoms
- Conclusion: The trial did not meet its primary efficacy endpoint, but established safety and tolerability of lithium in PSP patients
Interpretation:The negative trial results suggested several possibilities:
Dosing limitations: Achieving neuroprotective doses may require levels that approach toxicity
CNS penetration: Unclear if adequate brain concentrations were achieved
Disease stage: Treatment may need to start much earlier in disease course
Mechanism complexity: GSK-3β inhibition alone may be insufficient to modify disease progressionKey Learnings
Despite negative results, this trial provided valuable insights:
Safety profile: Lithium can be safely administered to PSP patients with appropriate monitoring
Biomarker data: CSF tau changes were measurable, informing future trial designs
Patient selection: Earlier-stage patients may be more likely to benefit
Dosing optimization: Lower doses (0.6-0.8 mEq/L) may provide better risk-benefitSeveral other GSK-3β inhibitors have been explored in tauopathies:
- [Tideglusib - Failed in AD trials](/genes/ide)
- CHIR99021 - Preclinical
- [Valproic acid - Also has GSK-3β effects, failed in PSP (NCT00385710)](/diseases/progressive-supranuclear-palsy)
- [Clinical Trials in Progressive Supranuclear Palsy](/genes/ran)
- [CBS/PSP Clinical Trials Guide](/diseases/progressive-supranuclear-palsy)
- [Valproic Acid PSP Trial](/diseases/progressive-supranuclear-palsy)
- [GSK-3β Inhibitor Therapy](/genes/th)
- [Tau Pathology Mechanisms](/genes/th)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[ClinicalTrials.gov: Lithium in PSP (NCT00703677)](https://clinicaltrials.gov/study/NCT00703677)
[Hampel H, et al, Lithium for the treatment of patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled trial. J Clin Psychiatry (2009)](https://pubmed.ncbi.nlm.nih.gov/19445141/)
[Tolosa E, et al, Lithium in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry (2009)](https://pubmed.ncbi.nlm.nih.gov/19366723/)
Detailed Mechanism of Action
GSK-3β Biology
Glycogen synthase kinase-3 beta (GSK-3β) is a serine/threonine kinase with diverse cellular functions:
- [Tau phosphorylation**: GSK-3β phosphorylates tau at multiple sites (Ser396, Ser404, Thr231, etc.)](/companies/gsk)
- [Wnt s](/companies/ad-wnt-signaling-developmental-pathway-companies)ignaling**: Key component of canonical Wnt pathway
- Glycogen metabolism: Original identified function
- Gene transcription: Modulates NFAT, CREB, and other transcription factors
- Apoptosis regulation: Controls pro-survival and pro-death pathways
In PSP and related tauopathies, GSK-3β activity is elevated, leading to excessive tau phosphorylation and aggregation.
Lithium's Molecular Targets
Lithium acts on multiple molecular pathways:
Primary target:
- GSK-3β: Direct inhibition via competitive mechanism at Mg²⁺ binding site
- IC₅₀ ~ 1-2 mM for therapeutic effects
Secondary targets:
- Inositol monophosphatase: Affects phosphoinositide signaling
- MAPK/ERK pathway: Modulates cell survival
- Neurotrophic signaling: Increases BDNF expression
Neuroprotective Mechanisms
Tau pathology reduction
- Inhibits pathological tau phosphorylation
- May reduce tau aggregation
- Promotes tau clearance mechanisms
Anti-apoptotic effects
- Activates AKT/PKB signaling
- Inhibits mitochondrial apoptosis pathway
- Protects against oxidative stress
Anti-inflammatory effects
- Modulates microglial activation
- Reduces pro-inflammatory cytokines
- May protect against neuroinflammation
Preclinical Evidence
Animal Models
- Tau transgenic mice: Lithium reduces tau phosphorylation and aggregation
- PSP models: Some benefit in behavioral assays
- Drosophila models: Extended lifespan in tauopathy models
Cell Culture Studies
- Protection against oxidative stress
- Reduction in tau phosphorylation
- Enhanced cell survival
Clinical Trial Design
NCT00703677 Details
- Phase: 2, randomized, double-blind, placebo-controlled
- Duration: 12 months
- Dose: Titration to serum levels 0.8-1.2 mEq/L
- Primary endpoint: Change in PSP Rating Scale (PSPRS)
- Secondary endpoints: MRI measures, CSF biomarkers
Patient Population
- Diagnosis: PSP (Richardson's syndrome)
- Disease duration: Typically 1-5 years
- Severity: Mild to moderate (H&Y 2-4)
- Exclusions: Significant comorbidities, prior lithium use
Outcome Measures
Primary
- Progressive Supranuclear Palsy Rating Scale (PSPRS)
- Standardized assessment of motor and cognitive function
Secondary
- MRI brain volumes
- CSF tau and phospho-tau levels
- Neuropsychological testing
- Quality of life measures
Trial Results Analysis
Efficacy Signals
Some clinical trials showed:
- Biomarker changes: Reduced CSF tau in some patients
- Slowed progression: Modest trends in clinical measures
- Subgroup effects: Possible benefit in certain patient populations
Limitations Observed
Therapeutic window: Neuroprotective doses close to toxic doses
CNS penetration: Uncertainty about brain concentrations
Trial duration: May need longer trials for disease-modifying effects
Patient selection: Possible need for earlier interventionSafety Profile
Lithium's side effect profile:
- Common: Weight gain, tremor, hypothyroidism
- Serious: Renal dysfunction, lithium toxicity
- Monitoring required: Regular serum level checks
Implications for Future Research
Lessons Learned
Target validation: GSK-3β remains a valid target despite trial results
Drug delivery: Need for better CNS-penetrant GSK-3β inhibitors
Biomarkers: Importance of biomarker-driven patient selection
Combination therapy: Potential for combination approachesOngoing Research
Other GSK-3β Inhibitors
- Tideglusib: Failed in AD trials but may have utility in other tauopathies
- AR-014: In development for AD
- CHIR99021: Preclinical
Combination Approaches
- Lithium + lithium + other agents
- GSK-3β inhibitors + anti-tau antibodies
- Synergistic targeting of multiple pathways
Comparison with Other Therapeutic Approaches
| Approach | Mechanism | Status | Evidence |
|----------|-----------|--------|----------|
| Lithium | GSK-3β inhibition | Completed | Modest |
| Anti-tau antibodies | Passive immunization | Ongoing | Growing |
| Small molecule inhibitors | Various | Preclinical/Phase 1 | Limited |
| Gene therapy | Tau reduction | Preclinical | Early |
Future Directions
Biomarker Development
- PET tau imaging: Select patients with significant tau pathology
- CSF phospho-tau: Monitor target engagement
- Genetic markers: Identify responders
- Extended-release lithium: More stable blood levels
- Brain-penetrant derivatives: Improved CNS targeting
- Combination products: Synergistic formulations
Regulatory Considerations
- Accelerated approval: Possible with strong biomarker data
- Companion diagnostics: Biomarker-driven indication
- Orphan drug status: PSP qualifies for orphan drug designation
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
- [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
- [Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
- [Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
- [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
- [Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
- [Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: NTN1
Related Analyses:
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Lithium Carbonate PSP Trial discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)